Table 1

 Baseline characteristics of the study patients. Values presented are median (range) unless otherwise stated

Infliximab + MTX group (n = 28)Placebo + MTX group (n = 14)
No statistically significant differences were found between treatment groups in any of the baseline characteristics using non-parametric tests (Mann-Whitney U test).
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index 0–10; BASFI, Bath Ankylosing Spondylitis Functional Index 0–10; VAS, visual analogue scale; EMS, early morning stiffness; CRP, C reactive protein; ASQoL, Ankylosing Spondylitis Quality of Life Index; NSAIDs, non-steroidal anti-inflammatory drugs; DMARDS, disease modifying antirheumatic drugs.
Male:female23:511:3
Age (years), mean41 (28–74)39 (30–56)
Disease duration (years)8 (0–41)10 (0–35)
HLA-B27 positive (%)9686
BASDAI6.9 (2.11–9.26)6.4 (3–10)
BASFI6.7 (1.9–9.63)6.0 (3.8–10)
VAS (mm):
    Pain day57.5 (17–96)66 (24–100)
    Pain night63.5 (11–100)76.5 (33–100)
    Enthesopathy75 (0–100)73 (9–100)
EMS (min)60 (15–120)75 (10–120)
CRP (mg/l)30.5 (10–153)30 (13–60)
ASQoL14 (2–18)13.5 (8–18)
Concomitant drugs, No (%) of patients):
    NSAIDs25 (89)12 (86)
    Oral corticosteroids5 (18)3 (25)
    DMARDs10 (36)4 (21)